source
- Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapyNovo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
- FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapsesThe U.S. Food and Drug Administration sent warning letters to three manufacturers of active pharmaceutical ingredients (APIs) based in China. Two of the companies were cited for refusing to provid…